DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo
Joan Tymon‐Rosario, Elena Bonazzoli, Stefania Bellone, Aránzazu Manzano, Silvia Pelligra, Adele Guglielmi, Barbara Gnutti, Nupur Nagarkatti, Burak Zeybek, Paola Manara, Luca Zammataro, Justin Harold, Dennis Mauricio, Natália Buza, Pei Hui, Gary Altwerger, Gulden Menderes, Elena Ratner, Mitchell Clark, Vaagn Andikyan, Gloria S. Huang, Dan‐Arin Silasi, Masoud Azodi, Peter E. Schwartz, Alessandro D. Santin
Topics & Concepts
In vivoHER2/neuMedicineAntibody-drug conjugateCancer researchTrastuzumabAntibodyImmunohistochemistryEpitopeSerous fluidPertuzumabCell cultureFlow cytometryCancerMolecular biologyPathologyMonoclonal antibodyImmunologyBiologyInternal medicineBreast cancerBiotechnologyGeneticsHER2/EGFR in Cancer ResearchEndometrial and Cervical Cancer TreatmentsEstrogen and related hormone effects